Last checked at 23 Mar 2022 07:00
4basebio Plc - Rapidly Produced Customisable Synthetic DNA4basebio Plc - Rapidly Produced Customisable Synthetic DNA
PR Newswire
London, March 22
23 March 2022
4basebio PLC
("4basebio", the "Company" or the “Group”)
Rapidly produced customisable synthetic DNA
4basebio PLC (AIM: 4BB), the life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA and mRNA vaccines, is pleased to announce the expansion of its synthetic DNA product offering.
Following 4basebio’s announcement in June 2021 regarding the development of its hpDNA™ and osDNA™ synthetic DNA constructs, 4basebio has now added opDNA™ and oeDNA™ to its product offering. This reflects the uniquely customisable characteristics of 4basebio’s synthetic DNA technology. The DNA product offering now comprises:
hpDNA™ is a double stranded linear DNA, covalently closed with single strand hairpins at the 5’ and 3’ ends and ideally suited for viral and non-viral vector applications. osDNA™ incorporates nucleotide modifications within the DNA backbone providing resistance to exonuclease degradation, as well as tuning of the immunostimulatory properties of the construct, making osDNA™ ideally suited for DNA vaccine applications. opDNA™ is a partially opened, linear, double stranded DNA product. Each opDNA™ molecule features a hairpin on either the 3’ or 5’ end, with an opposite open end. The open end of the construct can include an overhang or blunt end. This product is ideally suited as a template for IVT production of mRNA. oeDNA™ is a linear open-ended, double stranded DNA product where both 3’ and 5’ ends are open. Constructs can be generated with blunt ends, overhangs or any combination thereof. Like all 4basebio’s DNA products, oeDNA™ is resistant to degradation by exonuclease and hence suitable for in vivo applications. This format is ideal for genome editing by homology directed repair (HDR).Dr Heikki Lanckriet, CEO and CSO for 4basebio, commented: “The development of our DNA product range over the past twelve months underscores the flexibility of our technology and our ability to customise DNA for particular uses. We are able to modify our DNA constructs for an individual customer’s specific application.”
“Moreover, due to our synthetic process, we can move from receipt of a customer’s sequence to a first GMP-compliant multi-gram batch within three months, significantly quicker than plasmid alternatives.”
This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
For further enquiries, please contact:
| 4basebio PLC | +44 (0)12 2396 7943 |
| Heikki Lanckriet, CEO | |
| Cairn Financial Advisers LLP (Nominated Adviser) | +44 (0)20 7213 0880 |
| Jo Turner / Sandy Jamieson | |
| finnCap Ltd (Broker) | |
| Geoff Nash/Richard Chambers/Charlotte Sutcliffe/Nigel Birks | +44 (0)20 7220 0500 |
Notes to Editors
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic DNA for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is the intention of the Company to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. The immediate objectives of 4bb are to validate and scale its DNA synthesis and advance its collaborations to facilitate the functional validation of its DNA based products and cell and gene delivery solutions.
Forward-looking statements
This announcement may contain certain statements about the future outlook for the 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.